NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Integra Lifesciences Holdings Corp. IART
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.6B
▲ 1.5% vs FY2024
EPS · FY25
$-6.74
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-39.9%
Net margin · FY25
-31.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.6B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 32 cents on every revenue dollar this year.
Per share
USD -6.74
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-39.9%
Return on equity, FY2025
ROE
Operating margin-30.2%
Net margin-31.6%
Return on assets-13.5%
Each USD of equity lost 40 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -736,000.00
Share of profit-0.0%
Consecutive raises—
Growth
+3.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1.6%
+3.6%
+6.4%
+5.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.6B
total assets, end of FY2025
Total assetsUSD 3.6B
EquityUSD 1.0B
CashUSD 235.0M
Gross debtUSD 726.6M
Net debtUSD 491.5M
Current ratio2.54×
Net debt stands at 47% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
1.6
1.6
1.5
1.6
1.5
1.4
1.5
1.5
1.2
1.0
0.9
0.8
0.7
0.8
0.8
0.7
0.7
0.7
Operating income $B
−0.5
0.0
0.1
0.2
0.2
0.2
0.1
0.1
0.0
0.1
0.1
0.1
0.0
0.1
0.1
0.1
0.1
0.0
EBITDA $B
−0.4
0.1
0.2
0.3
0.2
0.2
0.1
0.2
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Income tax $B
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.1
0.0
0.1
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.5
−0.0
0.1
0.2
0.2
0.1
0.1
0.1
0.1
0.1
−0.0
0.0
−0.0
0.0
0.0
0.1
0.1
0.0
EPS, diluted $
−6.74
−0.09
0.84
2.16
1.98
1.57
0.58
0.72
0.82
0.94
−0.05
0.52
−0.74
1.44
0.95
2.17
1.74
0.96
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−39.9
−0.4
4.0
10.3
10.6
9.1
3.6
5.2
7.2
9.4
−0.5
5.0
−3.6
8.2
5.6
13.9
12.5
7.4
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
59 of 59
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed